Quantifying microstructural changes in Alzheimer's disease using Restriction Spectrum Imaging

使用限制光谱成像量化阿尔茨海默病的微观结构变化

基本信息

批准号：
10382916
负责人：
AZIZ M ULUG
金额：
$ 24.8万
依托单位：
CORTECHS LABS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-08-01 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10382916
关键词：
Affect Age Alzheimer disease detection Alzheimer&apos s Disease Alzheimer&apos s disease diagnosis Alzheimer&apos s disease pathology Alzheimer&apos s disease patient Alzheimer’s disease biomarker Amyloid beta-Protein Anatomy Axon Biological Markers Brain Brain region Classification Clinical Cognitive Computer software Cox Proportional Hazards Models Data Databases Dendrites Deposition Diagnosis Diffusion Diffusion Magnetic Resonance Imaging Disease Disease Progression Early Diagnosis Future Gender Goals Image Image Analysis Imaging Techniques Impaired cognition Individual Intervention Location Logistic Regressions Magnetic Resonance Imaging Maps Measures Methods Modeling Monitor Neurites Neurofibrillary Tangles Neurons Pathologic Pathology Pathway interactions Patients Performance Pharmacologic Substance Phase Population Positron-Emission Tomography Process Prognosis Reporting Restriction Spectrum Imaging Scanning Structure Techniques Therapeutic Effect Training base bioimaging density diffusion anisotropy early detection biomarkers gray matter imaging Segmentation imaging biomarker imaging modality in vivo indexing intervention effect mild cognitive impairment neuron loss predictive modeling tau Proteins tool treatment response white matter

项目摘要

Project Summary/Abstract The overall goal of this project is to deliver an automated diffusion image analysis tool to be used in a clinical setting that quickly evaluates the diffusion images in conjunction with MR volumetric images and reports diffusion-based microstructural parameters derived from segmented anatomical locations to determine Alzheimer’s disease status of patients. Alzheimer’s disease is characterized with β-amyloid deposits and neurofibrillary tangles preceding neuronal loss and cognitive decline. Hence quantitative volumetry and measures of neuronal function have been studied extensively as potential bioimaging markers. There has been increasing evidence of microstructural alterations in Alzheimer’s patients’ brains in addition to the volume and functional changes in neuronal bodies. While diffusion imaging has been used effectively in diseases involving specific white matter pathways, the recent advances in the diffusion imaging techniques particularly multi-compartmental models for successfully quantifying microstructural changes now enables the effective use of diffusion imaging in Alzheimer’s disease. Restriction Spectrum Imaging (RSI) is an advanced diffusion imaging method and currently can be used in MR scanners from major manufactures which have the capability to acquire multi-shell diffusion imaging. Recent studies of Alzheimer’s disease patients with diffusion techniques reported decreased diffusion anisotropy in multiple white matter tracts as well as increased diffusion in gray matter structures. Microstructural changes due to axonal and dendritic pathology, would reflect in diffusional measures. Advanced diffusion methods that are sensitive to neurite density and orientation are best qualified for elucidating the neuropathological changes preceding the cognitive decline in Alzheimer’s patients. Indeed, strong correlations between tau deposits measured by PET studies and neurite density index measured by advanced diffusion techniques were reported. There was also evidence of higher neurite dispersion in Alzheimer affected brain regions in addition to diffusion tensor imaging findings. Correlations with cognitive measures and diffusion parameters were also reported in a group of Alzheimer patients. Recent studies showed abnormal CSF measures of β-amyloid and tau levels associated with widespread alterations in white matter microstructures throughout the Alzheimer’s patients’ brains. Since CSF measures are well established biomarkers for AD pathology, in vivo and non-invasive determined diffusion parameters may convey AD related brain changes and predict future cognitive decline.

项目摘要/摘要该项目的总体目标是提供自动扩散图像分析工具在临床环境中使用，该环境迅速评估与MR结合的扩散图像体积图像和报告基于扩散的微结构参数分割了解剖位置，以确定患者的阿尔茨海默氏病状态。阿尔茨海默氏病的特征是β-淀粉样蛋白沉积物和神经纤维缠结前神经元丧失和认知能力下降。因此定量量和衡量标准神经元功能已被广泛研究为潜在的生物成像标记。有我们越来越有证据表明阿尔茨海默氏症患者大脑的微结构改变。神经元体的体积和功能变化。虽然扩散成像已经有效地用于涉及特定白质途径的疾病，最近的进步扩散成像技术，特别是多室模型的成功量化微观结构变化现在可以有效利用扩散成像阿尔茨海默氏病。限制光谱成像（RSI）是高级扩散成像方法和目前可以用于主要制造商的MR扫描仪获得多壳扩散成像的能力。阿尔茨海默氏病的最新研究扩散技术的患者报告说，多个白色的扩散各向异性降低物质区以及灰质结构中的扩散增加。微观结构变化由于轴突和树突状病理，将反映在扩散率测量中。先进的对神经元密度和方向敏感的扩散方法最适合阐明在阿尔茨海默氏症认知能力下降之前的神经病理学变化患者。实际上，通过PET研究测量的Tau沉积物与据报道，通过高级扩散技术测量的神经密度指数。有还证明了阿尔茨海默氏症受影响的大脑区域中神经蛋白较高的证据扩散张量成像发现。与认知测量和扩散的相关性一组阿尔茨海默氏症患者也报道了参数。最近的研究表明 β-淀粉样蛋白和tau水平的异常CSF测量与宽度变化有关整个阿尔茨海默氏症患者的大脑中的白质微观结构。由于CSF的测量是AD病理学，体内和非侵入性确定扩散的良好的生物标志物参数可能传达与AD相关的大脑变化并预测未来的认知下降。